Journal article icon

Journal article

Typhoid conjugate vaccines: Advancing the research and public health agendas

Abstract:
The disease burden of typhoid fever remains high in endemic areas in Asia and Africa, especially in children. Recent clinical trials conducted by the Typhoid Vaccine Acceleration Consortium show typhoid conjugate vaccine (TCV) to be safe, immunogenic, and efficacious at preventing blood culture-confirmed typhoid fever in African and Asian children. Pakistan, Liberia, and Zimbabwe recently introduced TCV through campaigns and routine childhood immunizations, providing protection for this vulnerable population. It is essential to continue this momentum while simultaneously filling data gaps—including typhoid complications—to inform decision-making on TCV introduction. A multidisciplinary approach including surveillance, water, sanitation, and hygiene investments, and large-scale TCV introduction is needed to decrease the burden and mortality of typhoid fever.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1093/infdis/jiab449

Authors

More by this author
Role:
Author
ORCID:
0000-0002-5746-1321
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Paediatrics
Oxford college:
St Cross College
Role:
Author
ORCID:
0000-0001-7361-719X


More from this funder
Funder identifier:
http://dx.doi.org/10.13039/100000002


Publisher:
Oxford University Press
Journal:
Journal of Infectious Diseases More from this journal
Volume:
224
Issue:
S7
Pages:
S781-S787
Publication date:
2021-09-16
Acceptance date:
2021-08-31
DOI:
EISSN:
1537-6613
ISSN:
0022-1899
Pmid:
34528085

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP